Viridian Therapeutics stock weighs Lumvoa uptake against losses
Viridian Therapeutics is evaluating the initial commercial success of its drug Lumvoa for thyroid eye disease against a Q2 2026 loss of USD 1.05 per share. RBC raised its price target for Viridian to USD 38.00, citing stronger-than-anticipated commercial rollout, while the company's financial performance still reflects its clinical-stage biotechnology status. Investors are watching to see if Lumvoa's launch will significantly increase commercial revenue and offset ongoing operational losses.
Total debt of Viridian Therapeutics, Inc. – HAN:1S1
This article provides financial information for Viridian Therapeutics, Inc. (1S1) listed on the Hannover Stock Exchange. It specifically highlights the company's total debt value over a given period, indicating changes in both absolute terms and percentages.
Discontinued operations of Viridian Therapeutics, Inc. – HAN:1S1
This article from TradingView states that Viridian Therapeutics, Inc. (HAN:1S1) has discontinued its operations. The brief update provides no further details on the reasons or implications of this discontinuation.
Does Strong Lumvoa Launch Change The Bull Case For Viridian Therapeutics Stock (VRDN)?
RBC Capital Markets reported a stronger-than-expected commercial launch for Viridian Therapeutics' thyroid eye disease drug, Lumvoa. This early traction suggests solid demand, which could help the company scale operations and impact its investment narrative, though Viridian remains loss-making. Analysts previously projected significant revenue and earnings growth by 2029 for Lumvoa and elegrobart, and this new information may influence future forecasts.
Viridian Therapeutics (NasdaqCM:VRDN) Stock Forecast & Analyst Predictions
Viridian Therapeutics (NasdaqCM:VRDN) is forecast to grow earnings by 63.7% and revenue by 52% per annum, with EPS expected to increase by 64.6%. The company, which recently received FDA approval for Lumvoa for Thyroid Eye Disease (TED), is projected to become profitable within the next three years, potentially breaking even in 2028. Despite positive clinical trial results for its TED treatments, analysts have revised revenue estimates downward, and the company faces risks related to shareholder dilution and share price volatility.
RBC Capital Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Raises Target Price to $38
RBC Capital has reiterated its Buy rating on Viridian Therapeutics (VRDN.US) and increased its price target for the company's stock to $38. This adjustment reflects continued confidence in the pharmaceutical company's future performance.
RBC Capital maintains Outperform rating on Viridian Therapeutics, $38 price target
RBC Capital has reaffirmed its Outperform rating for Viridian Therapeutics, setting a $38 price target. This target suggests a 76.1% upside from its previous close. The positive outlook is driven by strong early adoption and positive feedback from key opinion leaders regarding Viridian's Lumvoa, and the promising differentiated clinical profile of veligrotug for thyroid eye disease.
Viridian Therapeutics shifts focus to launch execution after FDA approves Lumvoa for thyroid eye disease.
Viridian Therapeutics has received FDA approval for Lumvoa, a treatment for thyroid eye disease (TED), and has begun treating patients. The company is now focusing on the successful launch of Lumvoa and leveraging its commercial infrastructure for both Lumvoa and its investigational drug elegrobart to improve operational efficiency and franchise economics. While the current valuation is high, the future profitability depends on effective commercialization, reimbursement, and expense management, requiring close monitoring of launch progress and financial stability.
(VRDN) Price Dynamics and Execution-Aware Positioning
Viridian Therapeutics Inc. (NASDAQ: VRDN) is showing weak sentiment across all time horizons, supporting a short bias. AI models have generated three trading strategies: a position trading strategy with a long entry, a momentum breakout strategy, and a risk hedging strategy with a short entry. The analysis highlights an exceptional 107.8:1 risk-reward setup targeting a 33.8% gain versus a 0.3% risk.
Alpha Buying: 4 Biotech Stocks a Healthcare Specialist Is Buying
This article highlights four biotech stocks that David Johnson of Caligan Partners, a healthcare-focused investment firm, has recently started buying. These companies—Sagimet Biosciences (SGMT), Viridian Therapeutics (VRDN), Artiva Biotherapeutics (ARTV), and Cellectar Biosciences (CLRB)—are identified as underfollowed with significant clinical and commercial catalysts. Caligan's investment strategy involves taking concentrated positions, providing financing, and actively engaging with management, indicating a deep conviction in the potential of these speculative, high-risk, high-reward opportunities.
Viridian Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conference
Viridian Therapeutics announced that its senior management will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on September 8, 2026. The company, which specializes in medicines for autoimmune and rare diseases, will provide a live webcast of the event on its investor relations website. Viridian is focused on treatments for thyroid eye disease with its FDA-approved Lumvoa™ and investigational elegrobart, and is expanding its pipeline to address other serious autoimmune conditions.
Viridian Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conference
Viridian Therapeutics announced that its senior management will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on September 8, 2026, at 12:45 PM ET. A live webcast will be available on the company's website. The company focuses on developing best-in-class medicines for autoimmune and rare diseases, including treatments for thyroid eye disease.
Viridian Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conference
Viridian Therapeutics, Inc. announced that its senior management will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on Tuesday, September 8, 2026, at 12:45 pm ET. A live webcast of the event will be available on the Investors section of the Viridian website, with a replay accessible afterwards. Viridian Therapeutics is a biotechnology company focused on developing medicines for autoimmune and rare diseases, with current efforts in thyroid eye disease (TED) and a pipeline for other autoimmune conditions.
Viridian Therapeutics, Inc. - Common Stock (Nasdaq:VRDN) Stock Quote
This article provides a stock quote for Viridian Therapeutics, Inc. (Nasdaq: VRDN), showing its current price, daily range, 52-week range, and key performance metrics. It also lists recent news and financial updates concerning the company, including FDA approvals, financial results, and investor conference participation, indicating active developments in its biopharmaceutical operations. The article also includes frequently asked questions about the company's public trading status and market capitalization.
Viridian Therapeutics CLO Jennifer Tousignant sells $348,194 in shares
Jennifer Tousignant, Chief Legal Officer at Viridian Therapeutics, sold 14,212 shares of the company's common stock for a total of $348,194 on August 19, 2026. This transaction occurred after she acquired 10,000 shares through exercised stock options. The sale follows a recent 11% gain in VRDN shares and comes as the company received FDA approval for its thyroid eye disease treatment, Lumvoa, prompting several analysts to reiterate positive ratings.
260,000 Shares in Viridian Therapeutics, Inc. $VRDN Purchased by Blue Owl Capital Holdings LP
Blue Owl Capital Holdings LP recently acquired 260,000 shares of Viridian Therapeutics, Inc. (VRDN) valued at approximately $4.8 million, making it their 23rd largest holding. Despite a recent quarterly loss, the company exceeded revenue expectations, and analysts maintain a "Moderate Buy" consensus with an average price target of $38.93. Insider activity also noted a sale of shares by Jennifer Tousignant.
Deep Track Capital, LP Trims Viridian Therapeutics (VRDN) Stake in Strategic Rebalancing
Deep Track Capital, LP has reduced its stake in Viridian Therapeutics Inc (VRDN) by 33.68%, selling over 1.8 million shares. This rebalancing act leaves the investment firm with a 1.08% portfolio allocation to VRDN, a clinical-stage biotechnology company focused on thyroid eye disease. Despite the reduction, Deep Track Capital maintains some confidence in Viridian's long-term prospects, even as the stock experiences volatility and financial metrics indicate challenges typical of early-stage biopharmaceutical companies.
Viridian Therapeutics CLO Jennifer Tousignant sells $348,194 in shares
Jennifer Tousignant, Chief Legal Officer at Viridian Therapeutics, sold 14,212 company shares for a total of $348,194 on August 19, 2026, at $24.50 per share. This transaction followed her acquisition of 10,000 shares through stock options at a lower exercise price. The sales occurred as VRDN shares experienced a gain and shortly after the company received FDA approval for its thyroid eye disease treatment, Lumvoa, leading to positive analyst outlooks.
Viridian Therapeutics (NASDAQ:VRDN) Insider Jennifer Tousignant Sells 14,212 Shares
Jennifer Tousignant, an insider at Viridian Therapeutics (NASDAQ:VRDN), sold 14,212 shares of the company's stock for a total of $348,194. This transaction occurred on August 19th, as disclosed in an SEC filing. Despite the insider sale, analysts maintain a "Moderate Buy" consensus rating for VRDN with an average price target of $38.93, even after the company reported a slight earnings per share miss but exceeded revenue estimates in its latest quarterly results.
Viridian Therapeutics (VRDN) legal chief sells 14,212 shares
Jennifer Tousignant, Chief Legal Officer of Viridian Therapeutics, Inc. (VRDN), exercised stock options to acquire 10,000 shares and subsequently sold a total of 14,212 shares of common stock at $24.50 per share on August 19, 2026. This transaction included 718 shares previously obtained through the company's Employee Stock Purchase Plan. Following these actions, Tousignant still holds 114,072 outstanding option shares from a grant dated March 3, 2025.
Steven Cohen’s Point72 discloses Viridian stake (VRDN)
Steven Cohen's Point72 Asset Management, along with Point72 Capital Advisors, Inc., and Steven A. Cohen, has disclosed a 5.0% beneficial ownership stake in Viridian Therapeutics, Inc. (VRDN). This stake, totaling 5,687,507 shares, is held by Point72 Associates, LLC, an investment fund managed by Point72 Asset Management. The entities report shared voting and dispositive power over these shares, as detailed in a recent SCHEDULE 13G SEC filing.
Viridian Therapeutics (VRDN) Could Be 83% Undervalued On Fresh Earnings Numbers
Viridian Therapeutics (VRDN) recently reported Q2 2026 earnings, showing increased revenue but continued net losses. Despite the company being flagged as trading at an 83% discount to its SWS DCF fair value estimate of $140.56, its Price-to-Sales (P/S) ratio of 38.1x is considered expensive compared to industry averages. Investors are presented with conflicting signals regarding its valuation, emphasizing the need for personal due diligence.
ETFs Investing in Viridian Therapeutics, Inc. Stocks
This article provides a comprehensive list of Exchange Traded Funds (ETFs) that hold Viridian Therapeutics, Inc. (1S1) stocks, sorted by market value. It details various ETFs, including their market value, weight of Viridian stock, issuer, management style, focus, expense ratio, assets under management (AUM), price, change percentage, relative volume, and 3-year NAV total return. The information helps investors understand how different ETFs offer exposure to Viridian Therapeutics with varying risk profiles and investment strategies.
Handelsbanken Fonder AB Invests $834,000 in Viridian Therapeutics, Inc. $VRDN
Handelsbanken Fonder AB has invested $834,000 in Viridian Therapeutics, Inc. (NASDAQ:VRDN) by acquiring 45,400 shares in the second quarter. The company maintains a "Moderate Buy" consensus rating from analysts with an average target price of $38.93, despite a recent quarterly loss of $1.05 per share. Viridian Therapeutics is a clinical-stage biopharmaceutical company developing antibody therapies for rare diseases like thyroid eye disease.
Viridian (NASDAQ: VRDN) insider to sell 14,212 shares in August 2026
An officer at Viridian Therapeutics, Inc. (VRDN), Jennifer Tousignant, plans to sell 14,212 shares of common stock valued at $348,194.00 around August 19, 2026. This sale is being made under Rule 144 and comprises shares obtained through restricted stock vesting, an ESPP purchase, and a stock option exercise. The filing indicates a neutral impact and sentiment for Viridian Therapeutics.
GSA Capital Partners LLP Invests $903,000 in Viridian Therapeutics, Inc. $VRDN
GSA Capital Partners LLP invested $903,000 in Viridian Therapeutics (NASDAQ:VRDN) by acquiring 49,177 shares during the second quarter. The article highlights other institutional investments, Viridian's recent earnings report (missing EPS but beating revenue estimates), and generally positive analyst sentiment with a "Moderate Buy" consensus rating and an average price target of $38.93. Viridian Therapeutics is a clinical-stage biopharmaceutical company focused on developing antibody therapeutics for rare and serious diseases.
Viridian Therapeutics (VRDN) Could Be 83% Undervalued On Fresh Earnings Numbers
Viridian Therapeutics (VRDN) recently released its Q2 2026 earnings, showing increased revenue but also widening losses. While the company's stock has seen recent positive momentum, its Price-to-Sales (P/S) ratio of 38.1x is significantly higher than industry averages, suggesting it is overvalued on this metric. However, a Discounted Cash Flow (DCF) model indicates the stock could be 83% undervalued, trading at $23.93 against an estimated fair value of $140.56, highlighting mixed signals for investors.
Viridian (NASDAQ: VRDN) CMO acquires 40K shares via option
Viridian Therapeutics, Inc. (VRDN) Chief Medical Officer, Radhika Tripuraneni, acquired 40,000 shares of common stock by exercising a stock option at $13.21 per share on August 14, 2026. This transaction increased her direct common stock holdings to 40,000 shares, with no derivative shares remaining from the exercised option. The option was fully vested and had an expiration date of July 1, 2034.
1,175,906 Shares in Viridian Therapeutics, Inc. $VRDN Bought by Rice Hall James & Associates LLC
Rice Hall James & Associates LLC has acquired a new stake of 1,175,906 shares in Viridian Therapeutics, Inc. (NASDAQ:VRDN) worth approximately $21.6 million, making it their 29th-largest portfolio holding. Despite the company reporting a quarterly EPS loss that narrowly missed analyst expectations, Viridian shares traded up 4.6% to $23.09. Analyst sentiment for VRDN remains favorable, with a "Moderate Buy" consensus and an average price target of $38.93.
93,414 Shares in Viridian Therapeutics, Inc. $VRDN Purchased by Merck & Co. Inc.
Merck & Co. Inc. recently acquired 93,414 shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) during the second quarter, representing 0.09% of Viridian’s outstanding stock and valued at approximately $1.716 billion. This acquisition highlights increased institutional interest in Viridian, with other major investors like Perceptive Advisors and Vanguard also boosting their stakes. Despite missing recent quarterly earnings expectations with an adjusted loss of $1.05 per share, analysts maintain a "Moderate Buy" consensus for VRDN with an average price target of $38.93.
Bank of America Corp DE Acquires 173,498 Shares of Viridian Therapeutics, Inc. $VRDN
Bank of America Corp DE significantly increased its stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN) by 17.5% in the first quarter, purchasing an additional 173,498 shares and now holding over 1.16 million shares valued at approximately $22.8 million. Despite Viridian Therapeutics reporting a quarterly loss that missed analyst expectations, its shares rose 4.6% to $23.09. Wall Street analysts maintain a broadly optimistic outlook, with a consensus "Moderate Buy" rating and a price target of $38.93.
T. Rowe Price Associates (VRDN) discloses 5.2% Viridian Therapeutics ownership in 13G
T. Rowe Price Associates, Inc. has disclosed a 5.2% beneficial ownership stake in Viridian Therapeutics, Inc. (VRDN) through a Schedule 13G SEC filing. As of June 30, 2026, the firm holds 5,748,426 shares of common stock, with sole voting power over 5,748,380 shares and sole dispositive power over all 5,748,426 shares. The filing indicates a passive investment, with T. Rowe Price Associates denying beneficial ownership despite its reported holdings.
Paradigm BioCapital reports 6.1% Viridian (VRDN) stake and 5.3% held by offshore fund
Paradigm BioCapital Advisors LP, its general partner, and Senai Asefaw M.D. have reported a beneficial ownership of 6,723,788 shares of Viridian Therapeutics (VRDN) common stock, representing 6.1% of the outstanding class as of June 30, 2026. Separately, Paradigm BioCapital International Fund Ltd. directly holds 5,896,154 shares, or 5.3% of the class. The ownership percentages are based on 110,427,682 shares outstanding as of May 11, 2026.
Deep Track group reports 3.25% Viridian Therapeutics (VRDN) ownership in latest filing
Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin have jointly reported a 3.25% ownership stake in Viridian Therapeutics (VRDN). This ownership, totaling 3,592,740 shares, is held with shared voting and dispositive power. The filing is based on 110,427,682 shares outstanding as of May 8, 2026, with the ownership information current as of June 30, 2026.
Trading the Move, Not the Narrative: (VRDN) Edition
This article provides an AI-generated analysis for Viridian Therapeutics Inc. (NASDAQ: VRDN), highlighting mixed sentiment and choppy conditions across different time horizons. It presents three distinct trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels, along with multi-timeframe signal analysis and support/resistance levels.
Viridian Therapeutics, Inc. Stock 12‑Month Price Target Cut to $36.07, Implies 58% Upside
The average 12-month price target for Viridian Therapeutics, Inc. (VRDN) stock has been lowered to $36.07 from $36.81 by 15 analysts, suggesting a potential upside of approximately 58% from its August 12 closing price. Despite the target cut, the consensus rating from 17 covering analysts remains a "Buy," with no "Holds" or "Sells."
Analysts Have Just Cut Their Viridian Therapeutics, Inc. (NASDAQ:VRDN) Revenue Estimates By 22%
Analysts have significantly cut Viridian Therapeutics, Inc.'s revenue estimates for 2026 by 22% to US$22 million, representing a 70% reduction from the previous year, and increased loss per share forecasts to US$3.97. Despite this downgrade, the stock price recently rose by 10%, indicating investor optimism. The consensus price target remained unchanged, suggesting that the business performance is broadly in line with expectations despite the lower earnings outlook.
Analysts Have Just Cut Their Viridian Therapeutics, Inc. (NASDAQ:VRDN) Revenue Estimates By 22%
Analysts have significantly revised down Viridian Therapeutics' 2026 revenue estimates by 22% to US$22 million, representing a 70% reduction from the past 12 months. Concurrently, per-share loss forecasts have increased to US$3.97. Despite a recent 10% stock price increase, the updated consensus suggests a more cautious outlook for the company's financial performance.
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Just Reported And Analysts Have Been Cutting Their Estimates
This article discusses Viridian Therapeutics, Inc. (NASDAQ:VRDN) after its recent earnings report, noting that analysts have begun cutting their estimates for the company. It will likely cover the implications of these revised forecasts on the stock's future performance and investor sentiment. The content will analyze the reasons behind the lowered expectations and what it means for Viridian's financial outlook.
Arrowstreet Capital Limited Partnership Has $455,000 Stock Holdings in Viridian Therapeutics, Inc. $VRDN
Arrowstreet Capital Limited Partnership significantly reduced its stake in Viridian Therapeutics (NASDAQ:VRDN) by 93.2% in the first quarter, now holding 23,279 shares valued at $455,000. Despite this, insider purchases, like Fairmount Funds Management's acquisition of 1.18 million shares for nearly $20 million, indicate growing insider confidence. Analysts maintain a "Moderate Buy" consensus with an average price target of $38.93, even though the company missed its latest quarterly EPS estimate.
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Viridian Therapeutics (NASDAQ:VRDN) recently reported quarterly results showing revenues significantly better than expected, though statutory losses per share were in line with forecasts. Despite the strong revenue performance, analysts have subsequently cut their revenue outlook for 2026 and increased their loss per share expectations, indicating a darker forecast. The consensus price target remained steady at US$36.63, but the revised estimates suggest the company's performance is expected to be substantially worse than the wider industry.
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Viridian Therapeutics' latest quarterly results showed revenues significantly exceeding expectations, though statutory losses per share were in line with forecasts. Despite the revenue beat, analysts have revised their 2026 forecasts downward, cutting revenue outlook and increasing loss per share expectations for the company. The consensus price target remained steady, but the updated forecasts suggest a gloomier outlook for Viridian Therapeutics, with projected revenue decline and increased losses, performing worse than the wider industry.
Renaissance Technologies LLC Takes $3.97 Million Position in Viridian Therapeutics, Inc. $VRDN
Renaissance Technologies LLC has acquired a new position in Viridian Therapeutics, Inc. (NASDAQ:VRDN), purchasing 203,100 shares valued at approximately $3.97 million. This move is part of broader institutional investor interest, with other firms also modifying their holdings. Despite Viridian Therapeutics missing its latest earnings estimate and posting losses, analysts generally maintain a "Moderate Buy" rating with a consensus price target of $38.93, significantly higher than its current stock price of $23.59.
RBC Adjusts Viridian Therapeutics PT to $36 From $35, Maintains Outperform Speculative Risk Rating
RBC has increased its price target for Viridian Therapeutics (VRDN) to $36 from $35, while reiterating an Outperform Speculative Risk rating. The company currently holds an average analyst rating of "buy" with a mean price target of $36.75.
State Street Corporation (NASDAQ: VRDN) discloses 5.5% Viridian Therapeutics ownership
State Street Corporation has reported a 5.5% ownership stake in Viridian Therapeutics, Inc. (VRDN), held through various subsidiaries including State Street Global Advisors entities. This significant holding comprises 6,124,976 shares of common stock, with shared voting and dispositive power, indicating a notable institutional position in the company. The disclosure was made via a SCHEDULE 13G SEC filing.
Viridian Therapeutics 2Q 2026: Revenue $284K, EPS $(1.05) — 10-Q Summary
Viridian Therapeutics reported its second-quarter 2026 results, showing early commercial revenue of $284K following FDA approval of Veligrotug (Lumvoa). The company experienced a wider net loss of $127.1M, reflecting its transition from an R&D to a commercial organization. Key highlights include the U.S. launch of Veligrotug, positive Phase 3 clinical trial results, and plans for pipeline expansion and a shift towards product sales.
Viridian Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Viridian Therapeutics Inc has released its earnings summary for the quarter that concluded on June 30. The report details the company's financial performance during this period, providing key insights into its operational results. This information is available through Refinitiv, with additional access offered via TradingView.
Viridian Therapeutics to See 'Minimal' Revenue Growth in H2, RBC Capital Markets Says
RBC Capital Markets forecasts "minimal" revenue growth for Viridian Therapeutics (VRDN) in the second half of the year. The report, published by MT Newswires, indicates that a more meaningful inflection in revenue is expected after this period. Access to the full article requires a premium Yahoo Finance subscription.
Press Release: Viridian Therapeutics Highlights Recent Business Progress and Reports Second Quarter 2026 Financial Results
Viridian Therapeutics has released its second quarter 2026 financial results, alongside an update on recent business developments. This announcement provides insights into the company's financial performance and strategic progress during the quarter.
Viridian Therapeutics reports Q2 2026 net loss of $127.1M, cash $981.5M after Lumvoa FDA approval
Viridian Therapeutics reported a Q2 2026 net loss of $127.1 million, with $981.5 million in cash, cash equivalents, and marketable securities. This report follows the FDA approval and U.S. commercial launch of Lumvoa for thyroid eye disease on June 26, 2026, and the company is on track for an elegrobart BLA submission in Q1 2027. The company also highlighted significant R&D and SG&A expenses, successful early commercial launch activities for Lumvoa, and pipeline progress for other treatments.
